Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry
© 2023 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
| Autores: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Tipo de recurso: | artículo |
| Estado: | Versión publicada |
| Fecha de publicación: | 2023 |
| País: | España |
| Institución: | Consejo Superior de Investigaciones Científicas (CSIC) |
| Repositorio: | DIGITAL.CSIC. Repositorio Institucional del CSIC |
| OAI Identifier: | oai:digital.csic.es:10261/352070 |
| Acceso en línea: | http://hdl.handle.net/10261/352070 https://api.elsevier.com/content/abstract/scopus_id/85151507775 |
| Access Level: | acceso abierto |
| Palabra clave: | COVID-19 Haematology Malignancy Nirmatrelvir SARS-CoV-2 |
| id |
ES_9f3ba8d5730966d1d5cbcdf060019f4e |
|---|---|
| oai_identifier_str |
oai:digital.csic.es:10261/352070 |
| network_acronym_str |
ES |
| network_name_str |
España |
| repository_id_str |
|
| dc.title.none.fl_str_mv |
Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry |
| title |
Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry |
| spellingShingle |
Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry Salmanton-García, Jon COVID-19 Haematology Malignancy Nirmatrelvir SARS-CoV-2 |
| title_short |
Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry |
| title_full |
Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry |
| title_fullStr |
Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry |
| title_full_unstemmed |
Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry |
| title_sort |
Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registry |
| dc.creator.none.fl_str_mv |
Salmanton-García, Jon Marchesi, Francesco Silva, Maria Gomes da Farina, Francesca Dávila-Valls, Julio Bilgin, Yavuz M. Glenthøj, Andreas Falces-Romero, Iker Doesum, Jaap van Labrador, Jorge Buquicchio, Caterina El-Ashwah, Shaimaa Petzer, Verena Van Praet, Jens Schönlein, Martin Dargenio, Michelina Méndez, Gustavo-Adolfo Meers, Stef Itri, Federico Giordano, Antonio Pinczés, László Imre Espigado, Ildefonso Stojanoski, Zlate López-García, Alberto Prezioso, Lucia Jaksic, Ozren Vena, Antonio Fracchiolla, Nicola S. González-López, Tomás José Čolović, Natasha Delia, Mario Weinbergerová, Barbora Marchetti, Monia Marqués de Almeida, Joyce Finizio, Olimpia Besson, Caroline Biernat, Monika M. Valković, Toni Lahmer, Tobias Cuccaro, Annarosa Ormazabal-Vélez, Irati Batinić, Josip Fernández, Noemí Jonge, Nick de Tascini, Carlo Anastasopoulou, Amalia N. Duléry, Rémy Príncipe, María Ilaria del Plantefeve, Gaëtan Papa, Mario Virgilio Nucci, Marcio Jiménez, Moraima Aujayeb, Avinash Hernández-Rivas, José Ángel Merelli, Maria Cattaneo, Chiara Blennow, Ola Nordlander, Anna Cabirta, Alba Varricchio, Gina Sacchi, Maria Vittoria Córdoba, Raúl Arellano-Orden, Elena Gräfe, Stefanie Wolf, Dominik Emarah, Ziad Ammatuna, Emanuele Hersby, Ditte Stampe Martín-Pérez, Sonia Nunes-Rodrigues, Raquel Rahimli, Laman Pagano, Livio Cornely, Oliver A. EPICOVIDEHA registry |
| author |
Salmanton-García, Jon |
| author_facet |
Salmanton-García, Jon Marchesi, Francesco Silva, Maria Gomes da Farina, Francesca Dávila-Valls, Julio Bilgin, Yavuz M. Glenthøj, Andreas Falces-Romero, Iker Doesum, Jaap van Labrador, Jorge Buquicchio, Caterina El-Ashwah, Shaimaa Petzer, Verena Van Praet, Jens Schönlein, Martin Dargenio, Michelina Méndez, Gustavo-Adolfo Meers, Stef Itri, Federico Giordano, Antonio Pinczés, László Imre Espigado, Ildefonso Stojanoski, Zlate López-García, Alberto Prezioso, Lucia Jaksic, Ozren Vena, Antonio Fracchiolla, Nicola S. González-López, Tomás José Čolović, Natasha Delia, Mario Weinbergerová, Barbora Marchetti, Monia Marqués de Almeida, Joyce Finizio, Olimpia Besson, Caroline Biernat, Monika M. Valković, Toni Lahmer, Tobias Cuccaro, Annarosa Ormazabal-Vélez, Irati Batinić, Josip Fernández, Noemí Jonge, Nick de Tascini, Carlo Anastasopoulou, Amalia N. Duléry, Rémy Príncipe, María Ilaria del Plantefeve, Gaëtan Papa, Mario Virgilio Nucci, Marcio Jiménez, Moraima Aujayeb, Avinash Hernández-Rivas, José Ángel Merelli, Maria Cattaneo, Chiara Blennow, Ola Nordlander, Anna Cabirta, Alba Varricchio, Gina Sacchi, Maria Vittoria Córdoba, Raúl Arellano-Orden, Elena Gräfe, Stefanie Wolf, Dominik Emarah, Ziad Ammatuna, Emanuele Hersby, Ditte Stampe Martín-Pérez, Sonia Nunes-Rodrigues, Raquel Rahimli, Laman Pagano, Livio Cornely, Oliver A. EPICOVIDEHA registry |
| author_role |
author |
| author2 |
Marchesi, Francesco Silva, Maria Gomes da Farina, Francesca Dávila-Valls, Julio Bilgin, Yavuz M. Glenthøj, Andreas Falces-Romero, Iker Doesum, Jaap van Labrador, Jorge Buquicchio, Caterina El-Ashwah, Shaimaa Petzer, Verena Van Praet, Jens Schönlein, Martin Dargenio, Michelina Méndez, Gustavo-Adolfo Meers, Stef Itri, Federico Giordano, Antonio Pinczés, László Imre Espigado, Ildefonso Stojanoski, Zlate López-García, Alberto Prezioso, Lucia Jaksic, Ozren Vena, Antonio Fracchiolla, Nicola S. González-López, Tomás José Čolović, Natasha Delia, Mario Weinbergerová, Barbora Marchetti, Monia Marqués de Almeida, Joyce Finizio, Olimpia Besson, Caroline Biernat, Monika M. Valković, Toni Lahmer, Tobias Cuccaro, Annarosa Ormazabal-Vélez, Irati Batinić, Josip Fernández, Noemí Jonge, Nick de Tascini, Carlo Anastasopoulou, Amalia N. Duléry, Rémy Príncipe, María Ilaria del Plantefeve, Gaëtan Papa, Mario Virgilio Nucci, Marcio Jiménez, Moraima Aujayeb, Avinash Hernández-Rivas, José Ángel Merelli, Maria Cattaneo, Chiara Blennow, Ola Nordlander, Anna Cabirta, Alba Varricchio, Gina Sacchi, Maria Vittoria Córdoba, Raúl Arellano-Orden, Elena Gräfe, Stefanie Wolf, Dominik Emarah, Ziad Ammatuna, Emanuele Hersby, Ditte Stampe Martín-Pérez, Sonia Nunes-Rodrigues, Raquel Rahimli, Laman Pagano, Livio Cornely, Oliver A. EPICOVIDEHA registry |
| author2_role |
author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author |
| dc.contributor.none.fl_str_mv |
Gilead Sciences Consejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72] |
| dc.subject.none.fl_str_mv |
COVID-19 Haematology Malignancy Nirmatrelvir SARS-CoV-2 |
| topic |
COVID-19 Haematology Malignancy Nirmatrelvir SARS-CoV-2 |
| description |
© 2023 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
| publishDate |
2023 |
| dc.date.none.fl_str_mv |
2023 2024 2024 |
| dc.type.none.fl_str_mv |
info:eu-repo/semantics/article http://purl.org/coar/resource_type/c_6501 Publisher's version info:eu-repo/semantics/publishedVersion |
| format |
article |
| status_str |
publishedVersion |
| dc.identifier.none.fl_str_mv |
http://hdl.handle.net/10261/352070 https://api.elsevier.com/content/abstract/scopus_id/85151507775 |
| url |
http://hdl.handle.net/10261/352070 https://api.elsevier.com/content/abstract/scopus_id/85151507775 |
| dc.language.none.fl_str_mv |
Inglés |
| language_invalid_str_mv |
Inglés |
| dc.relation.none.fl_str_mv |
EClinicalMedicine The underlying dataset has been published as supplementary material of the article in the publisher platform at https://doi.org/10.1016/j.eclinm.2023.101939 https://doi.org/10.1016/j.eclinm.2023.101939 Sí |
| dc.rights.none.fl_str_mv |
info:eu-repo/semantics/openAccess |
| eu_rights_str_mv |
openAccess |
| dc.format.none.fl_str_mv |
application/pdf |
| dc.publisher.none.fl_str_mv |
Elsevier |
| publisher.none.fl_str_mv |
Elsevier |
| dc.source.none.fl_str_mv |
reponame:DIGITAL.CSIC. Repositorio Institucional del CSIC instname:Consejo Superior de Investigaciones Científicas (CSIC) |
| instname_str |
Consejo Superior de Investigaciones Científicas (CSIC) |
| reponame_str |
DIGITAL.CSIC. Repositorio Institucional del CSIC |
| collection |
DIGITAL.CSIC. Repositorio Institucional del CSIC |
| repository.name.fl_str_mv |
|
| repository.mail.fl_str_mv |
|
| _version_ |
1869414911094816768 |
| spelling |
Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies: a report from the EPICOVIDEHA registrySalmanton-García, JonMarchesi, FrancescoSilva, Maria Gomes daFarina, FrancescaDávila-Valls, JulioBilgin, Yavuz M.Glenthøj, AndreasFalces-Romero, IkerDoesum, Jaap vanLabrador, JorgeBuquicchio, CaterinaEl-Ashwah, ShaimaaPetzer, VerenaVan Praet, JensSchönlein, MartinDargenio, MichelinaMéndez, Gustavo-AdolfoMeers, StefItri, FedericoGiordano, AntonioPinczés, László ImreEspigado, IldefonsoStojanoski, ZlateLópez-García, AlbertoPrezioso, LuciaJaksic, OzrenVena, AntonioFracchiolla, Nicola S.González-López, Tomás JoséČolović, NatashaDelia, MarioWeinbergerová, BarboraMarchetti, MoniaMarqués de Almeida, JoyceFinizio, OlimpiaBesson, CarolineBiernat, Monika M.Valković, ToniLahmer, TobiasCuccaro, AnnarosaOrmazabal-Vélez, IratiBatinić, JosipFernández, NoemíJonge, Nick deTascini, CarloAnastasopoulou, Amalia N.Duléry, RémyPríncipe, María Ilaria delPlantefeve, GaëtanPapa, Mario VirgilioNucci, MarcioJiménez, MoraimaAujayeb, AvinashHernández-Rivas, José ÁngelMerelli, MariaCattaneo, ChiaraBlennow, OlaNordlander, AnnaCabirta, AlbaVarricchio, GinaSacchi, Maria VittoriaCórdoba, RaúlArellano-Orden, ElenaGräfe, StefanieWolf, DominikEmarah, ZiadAmmatuna, EmanueleHersby, Ditte StampeMartín-Pérez, SoniaNunes-Rodrigues, RaquelRahimli, LamanPagano, LivioCornely, Oliver A.EPICOVIDEHA registryCOVID-19HaematologyMalignancyNirmatrelvirSARS-CoV-2© 2023 The Author(s). Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).[Background] Nirmatrelvir/ritonavir treatment decreases the hospitalisation rate in immunocompetent patients with COVID-19, but data on efficacy in patients with haematological malignancy are scarce. Here, we describe the outcome of nirmatrelvir/ritonavir treatment in a large cohort of the latter patients.[Methods] This is a retrospective cohort study from the multicentre EPICOVIDEHA registry (NCT04733729) on patients with haematological malignancy, who were diagnosed with COVID-19 between January and September 2022. Patients receiving nirmatrelvir/ritonavir were compared to those who did not. A logistic regression was run to determine factors associated with nirmatrelvir/ritonavir administration in our sample. Mortality between treatment groups was assessed with Kaplan–Meier survival plots after matching all the patients with a propensity score. Additionally, a Cox regression was modelled to detect factors associated with mortality in patients receiving nirmatrelvir/ritonavir.[Findings] A total of 1859 patients were analysed, 117 (6%) were treated with nirmatrelvir/ritonavir, 1742 (94%) were treated otherwise. Of 117 patients receiving nirmatrelvir/ritonavir, 80% had received ≥1 anti-SARS-CoV-2 vaccine dose before COVID-19 onset, 13% of which received a 2nd vaccine booster. 5% were admitted to ICU. Nirmatrelvir/ritonavir treatment was associated with the presence of extrapulmonary symptoms at COVID-19 onset, for example anosmia, fever, rhinitis, or sinusitis (aOR 2.509, 95%CI 1.448–4.347) and 2nd vaccine booster (aOR 3.624, 95%CI 1.619–8.109). Chronic pulmonary disease (aOR 0.261, 95%CI 0.093–0.732) and obesity (aOR 0.105, 95%CI 0.014–0.776) were not associated with nirmatrelvir/ritonavir use. After propensity score matching, day-30 mortality rate in patients treated with nirmatrelvir/ritonavir was 2%, significantly lower than in patients with SARS-CoV-2 directed treatment other than nirmatrelvir/ritonavir (11%, p = 0.036). No factor was observed explaining the mortality difference in patients after nirmatrelvir/ritonavir administration.[Interpretation] Haematological malignancy patients were more likely to receive nirmatrelvir/ritonavir when reporting extrapulmonary symptoms or 2nd vaccine booster at COVID-19 onset, as opposed to chronic pulmonary disease and obesity. The mortality rate in patients treated with nirmatrelvir/ritonavir was lower than in patients with targeted drugs other than nirmatrelvir/ritonavir.EPICOVIDEHA has received funds from Optics COMMIT (COVID-19 Unmet Medical Needs and Associated Research Extension) COVID-19 RFP program by GILEAD Science, United States (Project 2020-8223).Peer reviewedElsevierGilead SciencesConsejo Superior de Investigaciones Científicas [https://ror.org/02gfc7t72]202420242023info:eu-repo/semantics/articlehttp://purl.org/coar/resource_type/c_6501Publisher's versioninfo:eu-repo/semantics/publishedVersionapplication/pdfhttp://hdl.handle.net/10261/352070https://api.elsevier.com/content/abstract/scopus_id/85151507775reponame:DIGITAL.CSIC. Repositorio Institucional del CSICinstname:Consejo Superior de Investigaciones Científicas (CSIC)InglésEClinicalMedicineThe underlying dataset has been published as supplementary material of the article in the publisher platform at https://doi.org/10.1016/j.eclinm.2023.101939https://doi.org/10.1016/j.eclinm.2023.101939Síinfo:eu-repo/semantics/openAccessoai:digital.csic.es:10261/3520702026-05-22T06:33:51Z |
| score |
15,811543 |